medigraphic.com
ISSN 0016-3813 (Impreso)

2009, Número 6

<< Anterior Siguiente >>

Gac Med Mex 2009; 145 (6)


Trombólisis cerebral intravenosa en México. Una década perdida

Barinagarrementeria-Aldatz F

Idioma: Español
Referencias bibliográficas: 25
Paginas: 539-540
Archivo PDF: 34.84 Kb.


FRAGMENTO

La trombólisis cerebral por vía intravenosa es una estrategia para el tratamiento del infarto cerebral agudo utilizada desde 1996 en Estados Unidos. Entre 1995 y 1999, cuatro grandes estudios demostraron el beneficio de la trombólisis cerebral cuando se utilizaba dentro de las tres primeras horas del evento (NINDS, ECASS I y II, ATLANTIS). En 2004 se publicó un metaanálisis que confirmó que el rTPA era eficaz, especialmente si se empleaba tempranamente; en forma más reciente, el estudio ECASS3 ha demostrado la utilidad de la trombólisis intravenosa en un tiempo de hasta 4.5 horas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.

  2. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R; ECASS Study Group. Intravenous thrombolysis with tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-1025.

  3. Hacke W, Kaste M, Fieschi C, von Kummer R, Dávalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study investigators. Lancet 1998;352:1245-1251.

  4. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS Study. A randomized controlled trial. JAMA 1999;282:2019-2026.

  5. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-774.

  6. Cantú C; Investigadores PREMIER. Primer registro mexicano de isquemia cerebral. Presentado en la Reunión Anual de la Academia Mexicana de Neurología, Monterrey, Nuevo León, octubre de 2007.

  7. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 2001;32:1832-1840.

  8. Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke 2003;34:799-800.

  9. Johnston SC, Fung LH, Gillum LA, et al. Utilization of intravenous tissuetype plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke 2001;32:1061-1068.

  10. Wang DZ, Rose JA, Honings DS, Garwacki DJ, Milbrandt JC. Treating acute stroke patients with intravenous tPA: the OSF stroke network experience. Stroke 2000;31:77-81.

  11. Heuschmann PU, Kolominsky-Rabas PL, Roether J, Misselwitz B, Lowitzsch K, Heidrich J; German Stroke Registers Study Group. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA 2004;292:1831-1838.

  12. Citerio G, Galli D, Pesenti A. Early stroke care in Italy. A steep way ahead: an observational study. Emerg Med J 2006;23:608-611.

  13. Mosley I, Nicol M, Donnan G, Patrick I, Kerr F, Dewey H. The impact of ambulance practice on acute stroke care. Stroke 2007;38:2765-2770.

  14. Fraga JM

  15. Fraga JM

  16. Hill MD, Buchan AM; Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005;172:1307-1312.

  17. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-282.

  18. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-774.

  19. Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebocontrolled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators. Stroke 2000:31:811-816.

  20. Beguiristain JM, Mar J, Arrazola A. Coste de la enfermedad cerebrovascular aguda. Rev Neurol 2005;40:406-411.

  21. Fagan SC, Morgenstern LB, Petitta A, Ward RE, Tilley BC, Marler JR, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology 1998;50:883-890.

  22. Mar J, Begiristain JM, Arrazola A. Cost-effectiveness analysis of thrombolytic treatment for stroke. Cerebrovasc Dis 2005;20:193-200.

  23. Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous plasminogen activator for acute ischemic stroke in the United States. Stroke 2005;36:2500-2503.

  24. Yip TR, Demaerschalk BM. Estimated cost savings of increased use of intravenous tissue plasminogen activator for acute ischemic stroke in Canada. Stroke 2007;38:1952-1955.

  25. Hill MD, Sharma M. The economics of thrombolysis. Stroke 2007;38:1732-1733.




2020     |     www.medigraphic.com